https://scholars.lib.ntu.edu.tw/handle/123456789/557695
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Griesing S. | en_US |
dc.contributor.author | BIN-CHI LIAO | en_US |
dc.contributor.author | CHIH-HSIN YANG | en_US |
dc.creator | Griesing S.;Liao B.-C.;Chih-Hsin Yang | - |
dc.date.accessioned | 2021-04-23T05:56:25Z | - |
dc.date.available | 2021-04-23T05:56:25Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 0250-7005 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103205640&doi=10.21873%2fANTICANRES.14880&partnerID=40&md5=1f7da64aa6f82ca33a3050e45f354662 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/557695 | - |
dc.description.abstract | Background/Aim: Successful therapy of EGFR-mutant NSCLC remains a challenging task despite initial benefits with the usage of EGFR tyrosine kinase inhibitors. Cancer immunotherapy has shown promising results in certain tumors, but response rate in EGFR-mutant NCLC is low, because these tumors are thought to have weak immunogenicity. Materials and Methods: We used data from in vivo NSCLC databases as well as from in vitro cell culture experiments to investigate the regulation of CD73 by EGFR. Results: EGFR expression was correlated with CD73 expression in patients' datasets, with EGFR-mutant tumors showing higher expression than their EGFR wildtype counterparts. Treatment of EGFR-mutant NSCLC cell lines with EGFR TKI reduced expression of CD73 at both mRNA and protein level. Among EGFR downstream signaling pathways, the Ras-Raf-ERK pathway was involved in the regulation of CD73 expression directly via ERK1/2 without the engagement of RSKs or MSKs. Conclusion: The results of this study may provide novel therapeutic strategies for the treatment of oncogene-driven NSCLC. ? 2021 International Institute of Anticancer Research. All rights reserved. | - |
dc.publisher | International Institute of Anticancer Research | - |
dc.relation.ispartof | Anticancer Research | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | 1,4 diamino 1,4 bis(2 aminophenylthio) 2,3 dicyanobutadiene; 5' nucleotidase; 8 [4 (1 aminocyclobutyl)phenyl] 9 phenyl 1,2,4 triazolo[3,4 f][1,6]naphthyridin 3(2h) one; afatinib; epidermal growth factor receptor; epidermal growth factor receptor kinase inhibitor; gefitinib; ljh 685; ljh685; messenger RNA; mitogen activated protein kinase 1; mitogen activated protein kinase 3; osimertinib; ravoxertinib; ruxolitinib; sb 747641a; sb747641a; selumetinib; ulixertinib; unclassified drug; 5' nucleotidase; EGFR protein, human; epidermal growth factor receptor; glycosylphosphatidylinositol anchored protein; mitogen activated protein kinase; NT5E protein, human; adult; Article; cell culture; cell viability; controlled study; data analysis software; data base; HCC827 cell line; human; human cell; in vitro study; in vivo study; MAPK signaling; mRNA expression level; NCI-H441 cell line; non small cell lung cancer; oncogene; priority journal; protein expression; protein expression level; regulatory mechanism; wild type; gene expression regulation; genetics; lung tumor; non small cell lung cancer; pathophysiology; physiology; signal transduction; tumor cell line; 5'-Nucleotidase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Lung Neoplasms; MAP Kinase Signaling System; Signal Transduction | - |
dc.title | CD73 Is regulated by the EGFR-ERK signaling pathway in non-small cell lung cancer | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.21873/anticanres.14880 | - |
dc.identifier.pmid | 33788714 | - |
dc.identifier.scopus | 2-s2.0-85103205640 | - |
dc.relation.pages | 1231-1242 | - |
dc.relation.journalvolume | 41 | - |
dc.relation.journalissue | 3 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.orcid | 0000-0002-7092-0764 | - |
crisitem.author.orcid | 0000-0002-5586-5138 | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。